Back
Compare AU
Compare HYGG vs. CURE
Compare shares and ETFs on the ASX that you can trade on Pearler.
Overview
When it comes to investing in the Australian stock market, Exchange-Traded Funds (ETFs) are a popular choice. Two well-known options in the Australian Securities Exchange (ASX) are the Hyperion Global Growth Companies Fund - Active ETF (HYGG) and the Global X S&P Biotech ETF (CURE). In this comparison, we'll delve into these ETFs across various dimensions to help you make an informed investment decision.
Community Stats
HYGG | CURE | |
|---|---|---|
Popularity | Low | Low |
Pearlers invested | 119 | 81 |
Median incremental investment | $993.50 | $678.72 |
Median investment frequency | Monthly | Monthly |
Median total investment | $3,214.38 | $2,342.98 |
Average age group | > 35 | > 35 |
Key Summary
HYGG | CURE | |
|---|---|---|
Strategy | HYGG.AX was created on 2014-06-01 by Hyperion. The fund's investment portfolio concentrates primarily on total market equity. The Fund aims to achieve long-term returns above the benchmark, and minimise the risk of permanent capital loss | CURE.AX was created on 2018-11-08 by Global X. The fund's investment portfolio concentrates primarily on health care equity. The Fund aims to provide investors with a return that (before fees and expenses) tracks the performance of the S&P Biotechnology Select Industry Index. |
Top 3 holdings | Tesla Inc (12.96 %) Alphabet Inc Class A (9.61 %) Meta Platforms Inc Class A (7.48 %) | Twist Bioscience Corp (2.20 %) Moderna Inc (2.04 %) Natera Inc (1.81 %) |
Top 3 industries | Information Technology (40.46 %) Consumer Discretionary (27.08 %) Communication Services (16.69 %) | Health Care (100.00 %) Other (10.24 %) |
Top 3 countries | United States (92.29 %) Netherlands (3.76 %) France (2.37 %) | United States (96.62 %) United Kingdom of Great Britain and Northern Ireland (1.35 %) Switzerland (1.13 %) |
Management fee | 0.7 % | 0.45 % |
Key Summary
HYGG | CURE | |
|---|---|---|
Issuer | Hyperion | Global X |
Tracking index | MSCI World Index | S&P Biotechnology Select Industry |
Asset class | ETF | ETF |
Management fee | 0.7 % | 0.45 % |
Price | $6.43 | $76.16 |
Size | $3.363 billion | $49.412 million |
10Y return | 364.70 % | N/A |
Annual distribution yield (5Y) | 11.49 % | 0.03 % |
Market | ASX | ASX |
First listed date | 21/03/2021 | 12/11/2018 |
Purchase fee | $6.50 | $6.50 |
Community Stats
HYGG | CURE | |
|---|---|---|
Popularity | Low | Low |
Pearlers invested | 119 | 81 |
Median incremental investment | $993.50 | $678.72 |
Median investment frequency | Monthly | Monthly |
Median total investment | $3,214.38 | $2,342.98 |
Average age group | > 35 | > 35 |
Pros and Cons
HYGG | CURE | |
|---|---|---|
Pros |
|
|
Cons |
|
|
HYGG | CURE |
|---|---|
Lower exposure to US market | Higher exposure to US market |
Higher management fee | Lower management fee |
Higher price growth | Lower price growth |
Higher distribution yield | Lower distribution yield |